[go: up one dir, main page]

PT2266594E - Vegf para utilização no tratamento de distúrbios do sistema nervoso central - Google Patents

Vegf para utilização no tratamento de distúrbios do sistema nervoso central Download PDF

Info

Publication number
PT2266594E
PT2266594E PT101791275T PT10179127T PT2266594E PT 2266594 E PT2266594 E PT 2266594E PT 101791275 T PT101791275 T PT 101791275T PT 10179127 T PT10179127 T PT 10179127T PT 2266594 E PT2266594 E PT 2266594E
Authority
PT
Portugal
Prior art keywords
vegf
treatment
nervous system
central nervous
system disorders
Prior art date
Application number
PT101791275T
Other languages
English (en)
Inventor
Hans-Georg Kuhn
Kioumars Delfani
Ann Marie Janson Lang
Karlheinz Plate
Anne Schänzer
Frank-Peter Wachs
Ming Zhao
Original Assignee
Newron Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26983933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2266594(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Sweden Ab filed Critical Newron Sweden Ab
Publication of PT2266594E publication Critical patent/PT2266594E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/49—Platelet-derived growth factor [PDGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
PT101791275T 2001-09-19 2002-09-19 Vegf para utilização no tratamento de distúrbios do sistema nervoso central PT2266594E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32338101P 2001-09-19 2001-09-19
US32604401P 2001-09-28 2001-09-28

Publications (1)

Publication Number Publication Date
PT2266594E true PT2266594E (pt) 2015-08-05

Family

ID=26983933

Family Applications (2)

Application Number Title Priority Date Filing Date
PT2798797T PT1443955E (pt) 2001-09-19 2002-09-19 Pdgf-bb para o tratamento da doença de parkinson
PT101791275T PT2266594E (pt) 2001-09-19 2002-09-19 Vegf para utilização no tratamento de distúrbios do sistema nervoso central

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT2798797T PT1443955E (pt) 2001-09-19 2002-09-19 Pdgf-bb para o tratamento da doença de parkinson

Country Status (9)

Country Link
US (2) US7981863B2 (pt)
EP (3) EP1443955B1 (pt)
AU (1) AU2002334327B2 (pt)
CA (1) CA2461176C (pt)
CY (1) CY1113699T1 (pt)
DK (2) DK1443955T3 (pt)
ES (2) ES2396545T3 (pt)
PT (2) PT1443955E (pt)
WO (1) WO2003024478A1 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694038B2 (en) * 2000-04-06 2017-07-04 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
KR20030093316A (ko) * 2001-04-13 2003-12-06 휴먼 게놈 사이언시즈, 인코포레이티드 혈관 내피 성장 인자 ２
US20030176674A1 (en) * 2001-04-13 2003-09-18 Rosen Craig A. Vascular endothelial growth factor 2
US7943376B2 (en) * 2001-04-27 2011-05-17 Stem Cell Therapuetics Inc. Platelet derived growth factor (PDGF)-derived neurospheres define a novel class of progenitor cells
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
AU2003213078A1 (en) * 2002-02-14 2003-09-04 Buck Institute Neurogenerative or neurotrophic factors for mitigating a symptom of ischemia
GB0205772D0 (en) * 2002-03-12 2002-04-24 Gill Steven S Catheter
AU2003233119A1 (en) * 2002-05-08 2003-11-11 Neuronova Ab Modulation of neural stem cells with s1p or lpa receptor agonists
EP1622577A4 (en) * 2003-04-17 2007-09-26 Univ Leland Stanford Junior PREVENTION OF NEUROGENESE DEFICITES WITH ANTI-INFLAMMATORY AGENTS
US7998460B2 (en) * 2003-04-17 2011-08-16 The Board Of Trustees Of The Leland Stanford Junior University Prevention of deficits in neurogenesis with anti-inflammatory agents
JP4861177B2 (ja) * 2003-09-12 2012-01-25 ニューロノバ エービー 神経系の障害の処置
EP1663293A2 (en) * 2003-09-23 2006-06-07 Ludwig Institute For Cancer Research Vege-cor vege-d materials and methods for stimulation of neural stem cells
US20070269412A1 (en) 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
WO2005062962A2 (en) * 2003-12-19 2005-07-14 Imclone Systems Incorporated Methods and compositions for directing migration of neural progenitor cells
EP2365077B1 (en) * 2004-03-12 2013-05-08 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
ME01870B (me) * 2004-05-27 2011-04-30 Vib Vzw Liječenje amiotrofične lateralne skleroze
WO2006055743A2 (en) * 2004-11-18 2006-05-26 Franco, Wayne Compbination growth therapy and cell therapy for treatment of acute and chronic diseases of the organs
EP1837034A4 (en) * 2004-11-30 2009-08-05 Anges Mg Inc MEDICATION FOR ALZHEIMER'S DISEASE
US7629169B2 (en) * 2004-12-01 2009-12-08 Stem Cell Therapeutics Corp. Methods for the production of platelet-derived growth factor-responsive neural precursor cells
EA014886B1 (ru) * 2006-03-31 2011-02-28 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНА Eg5
US8147828B2 (en) 2006-04-17 2012-04-03 Ludwig Institute For Cancer Research Methods and compositions for modulation of blood-neural barrier
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
US20080044847A1 (en) * 2006-06-23 2008-02-21 Shusta Eric V Blood-Brain Barrier Model
CN100445373C (zh) * 2006-12-04 2008-12-24 山东大学 黄樟素氧化物在内皮细胞与神经干细胞培养体系中的应用
DE102007019162A1 (de) * 2007-04-20 2008-10-23 Johann Wolfgang Goethe-Universität Frankfurt am Main Verwendung von EGFL7 zur Modulation von Zellen
CN105267233B (zh) * 2008-03-05 2019-07-26 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因表达的组合物和方法
ES2376930B1 (es) * 2009-02-05 2013-01-24 Universidad Del Pais Vasco Método para el tratamiento de enfermedades neurodegenerativas.
US20100209399A1 (en) * 2009-02-13 2010-08-19 Celavie Biosciences, Llc Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects
EP2436387B1 (en) 2009-05-25 2018-07-25 Celgene Corporation Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
CN103688176A (zh) 2011-04-29 2014-03-26 细胞基因公司 利用cereblon作为预报因子治疗癌和炎性疾病的方法
CA2834832C (en) * 2011-06-01 2017-05-09 Universitat Heidelberg Vegf-d/vegfr2/3-mediated regulation of dendrites
EP2529745A1 (en) * 2011-06-01 2012-12-05 Universität Heidelberg VEGF-D/VEGFR mediated regulation of dendrites
US9415090B2 (en) 2011-06-01 2016-08-16 Universität Heidelberg VEGF-D/VEGFR2/3-mediated regulation of dendrites
CA3136093C (en) 2012-06-29 2025-07-08 Celgene Corporation METHODS FOR DETERMINING THE EFFICACY OF A DRUG USING PROTEINS ASSOCIATED WITH CEREBLON
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
RU2542385C2 (ru) * 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
CA2933464A1 (en) * 2013-12-09 2015-06-18 Thomas Jefferson University Use of abc drug efflux inhibitors in combination with anti-neurodegenerative drugs in the treatment of neurodegenerative disorders
US10369329B2 (en) 2014-01-30 2019-08-06 Renishaw Plc Neurosurgical apparatus and method
WO2015127351A1 (en) * 2014-02-24 2015-08-27 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
CN114081946A (zh) * 2014-03-12 2022-02-25 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
US10092555B2 (en) 2014-06-27 2018-10-09 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
WO2016092453A1 (en) * 2014-12-07 2016-06-16 Ramot At Tel-Aviv University Ltd. Prevention or reversal of apoe4 induced brain pathology by activation of vegf receptors
GB201506052D0 (en) 2015-04-09 2015-05-27 Renishaw Plc Movement disorder
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
WO2017135753A1 (ko) * 2016-02-05 2017-08-10 경북대학교 산학협력단 혈관내피성장인자를 과발현한 줄기세포를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물
RU2639175C1 (ru) * 2016-11-14 2017-12-20 Общество с ограниченной ответственностью "НекстГен" Способ индукции регенерации периферического нерва
US20230033523A1 (en) * 2021-07-30 2023-02-02 The Research Foundation For The State University Of New York Method of treating cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy (cadasil)
CN120583953A (zh) * 2023-02-09 2025-09-02 阿里斯制药有限公司 胎羊脑提取物用于管理神经退行性疾病的用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5219759A (en) 1987-04-22 1993-06-15 Chiron Corporation Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors
US4899919A (en) 1988-04-01 1990-02-13 Clumb Thomas E Self energizing fastener system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
IT1237435B (it) 1989-12-14 1993-06-04 Farmaco attivo nel ripristino della plasticita' neuronale.
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6294346B1 (en) * 1991-07-08 2001-09-25 Neurospheres Holdings, Ltd. Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
US5980885A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
US6071889A (en) * 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CH684573A5 (de) 1991-11-25 1994-10-31 Inst Molecular Biology Inc Verwendung von Wachstumsfaktoren zur Herstellung eines Arzneimittels für die Wachstumsförderung von Säugetiernerven.
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
EP0802800B1 (en) * 1993-08-12 2002-06-12 Neurotech S.A. Biocompatible immunoisolatory capsules containing genetically altered cells for the delivery of biologically active molecules
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0815221B1 (en) * 1995-03-02 2003-10-22 AMRAD Operations Pty.,Ltd. A novel growth factor and a genetic sequence encoding same
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5711316A (en) 1996-04-30 1998-01-27 Medtronic, Inc. Method of treating movement disorders by brain infusion
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
EP1060242A4 (en) 1998-01-23 2003-09-17 Imclone Systems Inc Purified populations of stem cells
EP1064382B1 (en) 1998-03-17 2008-08-20 Genentech, Inc. Polypeptides homologous to vegf and bmp1
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1109571B1 (en) * 1998-09-09 2004-03-03 Scios Inc. Methods of treating salt-dependent hypertension
US6432673B1 (en) * 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
CN1402733A (zh) * 1999-06-03 2003-03-12 人体基因组科学有限公司 血管生成蛋白及其应用
JP2003507349A (ja) 1999-08-18 2003-02-25 ザ ゼネラル ホスピタル コーポレーション 中枢神経系への損傷からの回復を促進する方法、組成物およびキット
CA2348906A1 (en) 1999-09-21 2001-03-29 Ryuichi Morishita Gene therapy for cerebrovascular disorders
AU2631001A (en) 2000-01-05 2001-07-16 Zymogenetics Inc. Novel fgf homolog zfgf11
US7582292B2 (en) * 2000-02-26 2009-09-01 Artecel, Inc. Adipose tissue derived stromal cells for the treatment of neurological disorders
CA2659656A1 (en) 2000-04-12 2001-10-18 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw The use of vegf165 to treat neuron disorders
US7943376B2 (en) 2001-04-27 2011-05-17 Stem Cell Therapuetics Inc. Platelet derived growth factor (PDGF)-derived neurospheres define a novel class of progenitor cells
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
WO2005016963A2 (en) * 2003-06-12 2005-02-24 Ludwig Institute For Cancer Research Heparin binding veger-3 ligands
US8114399B2 (en) * 2006-05-17 2012-02-14 Ludwig Institute For Cancer Research Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
WO2008066630A2 (en) * 2006-10-27 2008-06-05 Caritas St. Elizabeth Medical Center Of Boston, Inc. Methods for reprogramming adult somatic cells and uses thereof

Also Published As

Publication number Publication date
EP2266594A1 (en) 2010-12-29
HK1068501A1 (en) 2005-04-22
US20120077741A1 (en) 2012-03-29
CY1113699T1 (el) 2016-06-22
DK2266594T3 (en) 2015-08-10
CA2461176C (en) 2013-11-05
EP2289537A1 (en) 2011-03-02
EP1443955B1 (en) 2012-09-12
PT1443955E (pt) 2012-12-26
AU2002334327B2 (en) 2006-05-04
CA2461176A1 (en) 2003-03-27
WO2003024478A9 (en) 2003-06-05
EP2266594B1 (en) 2015-05-27
ES2546093T3 (es) 2015-09-18
WO2003024478A1 (en) 2003-03-27
US7981863B2 (en) 2011-07-19
US20030203844A1 (en) 2003-10-30
HK1152243A1 (en) 2012-02-24
ES2396545T3 (es) 2013-02-22
DK1443955T3 (da) 2013-01-02
EP1443955A1 (en) 2004-08-11

Similar Documents

Publication Publication Date Title
PT2266594E (pt) Vegf para utilização no tratamento de distúrbios do sistema nervoso central
PL373626A1 (en) Treatment for central nervous system disorders
PL1660057T3 (pl) Terapia łączona do leczenia zaburzeń związanych z neowaskularyzacją gałki ocznej
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
AU2003249983A8 (en) Piperidines useful for the treatment of central nervous system disorders
IL159771A0 (en) Combinations for the treatment of inflammatory disorders
AU9112201A (en) Pulmonary delivery in treating disorders of the central nervous system
PL378108A1 (pl) Leczenie łączone do terapii zapalnych zaburzeń immunologicznych
IL160389A0 (en) Use of flibanserin for the treatment of sexual disorders
IL161267A0 (en) Combinations for the treatment of immunoinflammatory disorders
SI1474416T1 (sl) Derivati dihidrobenzodiazepin-2-ona za zdravljenje nevroloskih motenj
GB0007193D0 (en) Treatment of movrmrnt disorders
IL176581A0 (en) Immunomodulatory compounds for the treatment of central nervous system disorders
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
HUP0501017A3 (en) Methods and compositions for treatment of central nervous system disorders
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
PL368556A1 (en) Methods for treating or preventing skin disorders using cd2-binding agents
IL150289A0 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine
IL150290A0 (en) The use of mirtazapine for the treatment of sleep disorders
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
IL155817A0 (en) Combination therapy for estrogen-dependent disorders
PL351554A1 (en) Osanetant in the treatment of mood disorders
ZA200505996B (en) Combination therapy for the treatment of immunoinflammatory disorders
GB0010496D0 (en) Treatment of conditions of the central nervous system